Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery
The purpose of this clinical study is to assess the safety and immunogenicity of the immunotherapeutic product GSK 2302032A when given to Non-Small Cell Lung Cancer (NSCLC) patients, after tumor removal by surgery.
Lung Cancer, Non-Small Cell
BIOLOGICAL: Immunotherapeutic GSK2302032A, different formulations
Occurrence of dose-limiting toxicities during study treatment, During the study treatment period (up to 112 weeks, approximately 2 years and 2 months)|Occurrence of dose-limiting toxicities during study follow-up, 12 months after concluding visit (week 112)|Anti-PRAME humoral immune response, Assessed post-dose 4 (Week 12)|Anti-PRAME humoral immune response, Throughout the study (Day 0 until 12 months after concluding visit (week 112))
Occurrence of adverse events (AEs) and serious adverse events, During the whole study treatment period until 30 days after the last treatment administration.|The anti-PRAME cellular (T-cell) response, At 6 defined time-points during the study (Week 0, 12, 24, 72 and 112) and follow-up period (6 months later).|The anti-PRAME humoral immunogenicity, At 10 defined timepoints during the study (Week 0, 6, 12, 24, 48, 72, 96, 112), and follow-up period (6 and 12 months later).
The purpose of this clinical study is to assess the safety and immunogenicity of the immunotherapeutic product GSK 2302032A when given to Non-Small Cell Lung Cancer (NSCLC) patients, after tumor removal by surgery.